SPY414.88-1.19 -0.29%
DIA339.39-1.91 -0.56%
IXIC13,954.27+4.05 0.03%

BRIEF-GBT Expands Sickle Cell Disease Pipeline With Exclusive In-License Of Two Novel Small Molecule Programs From Sanofi S.A.

· 03/16/2021 07:06
BRIEF-GBT Expands Sickle Cell Disease Pipeline With Exclusive In-License Of Two Novel Small Molecule Programs From Sanofi S.A.

- Global Blood Therapeutics Inc GBT.O:

  • GBT EXPANDS SICKLE CELL DISEASE PIPELINE WITH EXCLUSIVE IN-LICENSE OF TWO NOVEL SMALL MOLECULE PROGRAMS FROM SANOFI S.A.

  • GLOBAL BLOOD THERAPEUTICS - UNDER AGREEMENT, GBT WILL CONDUCT ALL RESEARCH, DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES WORLDWIDE

  • GLOBAL BLOOD THERAPEUTICS - SANOFI WILL RECEIVE UPFRONT PAYMENT & IS ENTITLED TO PAYMENTS UP TO ABOUT $353 MILLION UPON ACHIEVEMENT OF SOME MILESTONES

  • GLOBAL BLOOD THERAPEUTICS INC - SANOFI IS ALSO ENTITLED TO SINGLE-DIGIT TIERED ROYALTIES ON WORLDWIDE NET SALES

Source text for Eikon: ID:nGNX1s6GCd

Further company coverage: GBT.O


((Reuters.Briefs@thomsonreuters.com;))